282 related articles for article (PubMed ID: 21775465)
1. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin.
Vigan R; Neil SJ
J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465
[TBL] [Abstract][Full Text] [Related]
2. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.
Dubé M; Roy BB; Guiot-Guillain P; Mercier J; Binette J; Leung G; Cohen EA
J Virol; 2009 May; 83(9):4574-90. PubMed ID: 19244337
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.
Petit SJ; Blondeau C; Towers GJ
J Gen Virol; 2011 Dec; 92(Pt 12):2937-2948. PubMed ID: 21900423
[TBL] [Abstract][Full Text] [Related]
5. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
6. Vpu binds directly to tetherin and displaces it from nascent virions.
McNatt MW; Zang T; Bieniasz PD
PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
[TBL] [Abstract][Full Text] [Related]
7. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
[TBL] [Abstract][Full Text] [Related]
8. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
10. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
12. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
14. Lack of adaptation to human tetherin in HIV-1 group O and P.
Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
16. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
18. A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.
Douglas JL; Bai Y; Gustin JK; Moses AV
Virology; 2013 Jul; 441(2):182-96. PubMed ID: 23582304
[TBL] [Abstract][Full Text] [Related]
19. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
20. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
Dotson D; Woodruff EA; Villalta F; Dong X
J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
